Market Overview

Benzinga Quick Stats: Merus IPO

Related MRUS
Earnings Scheduled For July 11, 2017
The Current State Of The Breast Cancer Treatment Space
Merus BV (NYSE: MRUS) is an immuno-oncology company that develops antibody therapeutics.
Initial range for 4.33 million shares at $14-$16/share
Morning of the IPO cut the price to $10
Shares opened for trade at $9.75
Spiked to $10.73, but fell to $10.04 by market close
On Friday, shares were up about 1 percent at $10.16 about three hours into trading.

Biotech IPOs have struggled lately.

NovoCure Limited (NASDAQ: NVCR) debuted last fall at $22/share and fell 17 percent the day after. On Thursday, NovoCure closed at $11.60.

MyoKardia, Inc. (NASDAQ: MYOK) initially priced their shares at $15-$17, revised that to $10 the day before the offering happened, and now sits at $12.11 as of Thursday.

Posted-In: News IPOs Trading Ideas


Related Articles (MYOK + MRUS)

View Comments and Join the Discussion!